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Abstract
This study aims to co-microencapsulate the Ruellia tuberosa L. and Cosmos caudatus K. extracts, with chitosan–sodium
tripolyphosphate (Na-TPP) as coating material. α-Amylase inhibition and antioxidant assays were conducted to determine
the potential of microcapsules used as antidiabetic agents. The microcapsules were manufactured under the influences of
pH, Na-TPP concentration, and stirring time. The optimum microencapsulation conditions were selected based on the
highest encapsulation efficiency. The optimum microencapsulation conditions were a pH of 4, Na-TPP concentration of
0.15% (w/v), and stirring time of 60 min. The microcapsules exhibited an IC 50 (inhibitory concentration) value of 223.64
± 0.81 µg/mL and an α-amylase inhibition and antioxidant activity of 104.05 ± 0.88 µg/mL. The test for the release of
bioactive compounds from microcapsules was conducted in HCl pH 1.2 and phosphate buffer pH 7.4 for 30–120 min.
Results showed that 5.99% and 58.96% of bioactive compounds were released at pH 1.2 and 7.4, respectively, in 120
min. The Fourier transform infrared spectra showed the P=O functional group vibrations from Na-TPP at 1,213.71 cm−1
and C–N stretching vibrations from chitosan at 1,155.23 cm−1. Characterization with scanning electron microscopy and
particle size analysis indicated that the microcapsules were spherical and had a mean diameter of 132.08 µm. The current
study demonstrated that co-microencapsulation is a promising multifaceted approach for the enhancement of the pharmaceutical applications of plant extract combinations.
Keywords: Ruellia tuberosa L., Cosmos caudatus K., co-microencapsulation, chitosan, Na-TPP

caudatus K. plants are found in East Africa, Europe, and
Southeast Asia (e.g., Indonesia) [7, 8]. This plant has antidiabetic, antihypertensive, and anti-inflammatory activities [9]. Flavonoids, polyphenols, saponins, alkaloids,
and tannins are the bioactive compounds found in C. caudatus K. [10]. The flavonoid compounds in the leaf extract of C. caudatus K., such as genistin, oroxin B, and
quercetin (QE), have antidiabetic and antioxidant activities proven through in vitro studies [11].

Introduction
Ruellia tuberosa L. or pletekan is a widely distributed
herbal plant in Indonesia. This plant has been used as an
antidiuretic, antidiabetic, analgesic, antipyretic, and antihypertensive [1, 2]. In general, R. tuberosa L. has been
used as a natural antidiabetic remedy [2]. The bioactive
compounds in the root extract of R. tuberosa L. are phytosterols and flavonoids. Phytosterol compounds have
antioxidant activity needed in diseases associated with
free radicals, such as diabetes [3]. The flavonoid compounds in the root extract of R. tuberosa L., such as sorbifolin, cirsimarin, cirsimaritin, and cirsiol 4′-glucoside,
have been proposed to have antidiabetic activity [4].
Moreover, both in vivo and in silico studies have been
conducted to explore the potential of the R. tuberosa L.
extract as an antidiabetic agent [4–6].

The number of diabetes mellitus (DM) cases in Indonesia
has increased over the past 6 years [12]. More than 90%
of cases worldwide are caused by Type 2 DM [6]. Based
on the International Diabetes Federation report, the number of people with Type 2 DM was 7.3 million in 2009
and increased to 10.3 million in 2017 [12]. Type 2 DM is
a metabolic disorder caused by the resistance of body
cells to insulin [6, 13]. As a result, insulin secreted by
pancreatic β-cells cannot maintain normal blood glucose
levels [6]. The development of Type 2 diabetes is also
influenced by postprandial hyperglycemia, which is an

Apart from R. tuberosa L., Cosmos caudatus K. or kenikir, an herb from Latin America, has also been widely
proposed to have various biological functions. C.
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increase in blood glucose levels because of carbohydrate
absorption [14]. α-Amylase is one of the targeted enzymes in the treatment of Type 2 DM. α-Amylase hydrolyzes the α-glycosidic bonds in starch into oligosaccharides (i.e., lactose, maltose, and sucrose). α-Amylase inhibition prevents further digestion of carbohydrates; as a
result, the body absorbs less glucose [15]. Furthermore,
in Type 2 DM, hyperglycemia increases reactive oxygen
species production and oxidative stress. Increased oxidative stress induces the development of complications,
such as myocardial injury, diabetic retinopathy, and cardiovascular disease. Therefore, antioxidants are also
needed for Type 2 DM treatment [16].
Several previous studies proposed that R. tuberosa L. and
C. caudatus K. have antidiabetic and antioxidant activities [3–6, 11]. As a result, the use and development of
herbal plants in medicine have increased. However, the
two plants have never been combined. Therefore, further
research is needed to determine the biological activity of
the combination of R. tuberosa L. and C. caudatus K. as
a new drug candidate for Type 2 DM.

97

polycations form cross-links with polyanions, such as sodium tripolyphosphate (Na-TPP) [23, 25]. The addition
of Na-TPP as a cross-linking agent strengthens the chitosan matrix, resulting in a stable coating material [26].
Several factors, including the solubility of chitosan, NaTPP concentration, and stirring time, influence microencapsulation. Chitosan is soluble in organic acid solvents
at pH 4–6.5 [24]. The pH of the acetic acid solution, NaTPP concentration, and stirring time affect the microencapsulation efficiency [27–29].
This study aims to investigate the encapsulation process
using the spray drying technique. The coating material
used is chitosan polymer with Na-TPP as the cross-linking agent. Several factors, such as pH, Na-TPP concentration, and stirring time, were investigated to determine
the optimum microencapsulation conditions. Furthermore, to determine its potential as a Type 2 DM drug,
activity tests were conducted on the resulting microcapsules under the optimum microencapsulation conditions
through α-amylase inhibition and antioxidant assays.

Materials and Methods
In developing antidiabetic drug candidates, oral bioavailability, which is the number of bioactive compounds that
can reach the systemic circulation, needs to be considered. Therefore, the molecular properties of the bioactive
compounds in the R. tuberosa L. and C. caudatus K. extracts, which limit their bioavailability, need to be understood [17]. Cirsimarin is a bioactive compound with low
permeability, whereas QE is a hydrophobic compound
with low solubility. As a result, fewer bioactive compounds are absorbed by the digestive tract. Furthermore,
the expected efficacy is not achieved because of the lack
of bioactive compounds in the systemic circulation [18].
The bioavailability of bioactive compounds in R. tuberosa L. and C. caudatus K. could be improved using the
encapsulation technique [19]. The microencapsulation
technique is used to retain the active ingredients in plant
extracts and control the release of extracts entering the
systemic circulation [20]. Microencapsulation is defined
as the coating of the core material by polymers to produce
particles with the size of 5–5,000 µm [21]. For microencapsulation, spray drying is the most frequently used
method. The extract is dispersed into a polymer solution
and sprayed in a high-temperature chamber. Then, the atomization and evaporation processes of the solvent are
conducted to obtain dry particles [22]. A common technique used to prepare coating solutions is the ionic gelation technique [23].
The ionic gelation technique is based on the formation of
a polyelectrolyte complex between polycations and polyanions. Chitosan is a biopolymer that is widely used as
a coating material in microencapsulation [23]. Chitosan
is nontoxic and biodegradable and has low solubility in
water [20–24]. Moreover, the amino group of chitosan
can be protonated at pKa below 6.5. Then, these
Makara J. Sci.

Materials and instruments. The materials used in this
research were R. tuberosa L. root powder and C.
caudatus K. leaf powder obtained from UPT
Laboratorium Herbal Materia Medica, Batu, East Java,
Indonesia. The chemicals used in this research include
ethyl alcohol (99.7%), glacial acetic acid (secondary
pharmaceutical standard), α-amylase from Aspergillus
oryzae (≥150 units/mg protein), chitosan (low Sabarudin
weight, 50,000–190,000 kDa), Na-TPP (technical grade,
85%), aluminum chloride (AlCl3), 3,5-dinitrosalicylic
acid (DNS) reagent (≥98%, high-performance liquid
chromatography grade), 2,2-diphenyl-1-picrylhydrazyl
(DPPH, reagent grade), Tween-80, and soluble starch
(from potato, American Chemical Society grade). The
instruments used in this research were the Shimadzu UV–
Vis spectrophotometer, Shimadzu Prestige 21 FTIR
spectrometer, CILAS 1090 particle size analyzer (PSA),
and SEM TM 3000 Hitachi.
Extract preparations. A total of 250 g of R. tuberosa L.
root powder was macerated three times in 1 L of 96%
ethanol for 24 h. Then, the extracts were filtered and
concentrated using a rotary evaporator at 50 C and 120
rpm. The extracts were stored at 4 C for further use.
A total of 250 g of C. caudatus K. leaf powder was
dissolved in 1 L of 96% ethanol solvent and macerated
three times for 24 h. The extract was filtered using
Whatman filter paper. Then, the solvent was evaporated
using a rotary evaporator at 68 C and 120 rpm. The
concentrated extract obtained was stored at 4 C for
subsequent use.
R. tuberosa L. and C. caudatus K. extracts weighing 1 g
each were dissolved in 0.2 mL of distilled water and 4.8
June 2022  Vol. 26  No. 2
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mL of ethanol p.a. Then, 100 mL of Tween-80 0.1%
(w/v) was added and stirred at 500 rpm. Furthermore, the
mixture was concentrated to obtain a combination of R.
tuberosa L. and C. caudatus K. extracts.
Co-microencapsulation of R. tuberosa L. and C.
caudatus K. Extracts. The preparation and comicroencapsulation of R. tuberosa L. and C. caudatus K.
extracts were conducted by weighing 500 mg of the
combined extract. Then, the combined extract was
dissolved in 0.4 mL of distilled water and 9.6 mL of
ethanol p.a. The sample solution was mixed with 0.1%
(w/v) chitosan in 1% (w/v) acetic acid solution (pH 3, 4,
5, and 6). Subsequently, 0.1% (w/v) Na-TPP solution was
added and stirred at a constant speed of 900 rpm for 60
min. Finally, the solution was spray-dried with an inlet
temperature of 105 C, outlet temperature of 85 C, and
air pressure of 1 bar.
The parameters affecting co-microencapsulation were
investigated in several stages. First, the effect of the
variation of pH was analyzed. The optimum pH condition
was used to determine the effect of Na-TPP concentration
at 0.15%, 0.20%, 0.25%, and 0.3% (w/v). Meanwhile, the
other conditions remained the same. Finally, the same
procedure was used to determine the effect of stirring
time (i.e., 30, 60, 90, and 120 min) under optimum pH
and Na-TPP concentration conditions. The optimum
conditions for each parameter were determined using the
encapsulation efficiency (EE, %).
Encapsulation efficiency. EE indicates the effectiveness
of the coating material in encapsulating and protecting
the extract [30]. EE was calculated using the following
equation:
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%)
=

𝑇𝑜𝑡𝑎𝑙 𝑓𝑙𝑎𝑣𝑜𝑛𝑜𝑖𝑑 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑐𝑎𝑝𝑠𝑢𝑙𝑒𝑠
× 100%
𝑇𝑜𝑡𝑎𝑙 𝑓𝑙𝑎𝑣𝑜𝑛𝑜𝑖𝑑 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑠

The total flavonoid content (TFC) was determined using
the AlCl3 colorimetric method. For TFC determination,
the standard curves of QE solutions with various
concentrations (5–20 µg/mL) were obtained. The QE
standard solution and samples (extracts and
microcapsules) were pipetted (as much as 0.6 mL) and
placed in a test tube. Then, the solution was mixed with
0.6 mL of 2% AlCl3 and incubated at room temperature
for 23 min. The mixed solution was measured using a
UV–Vis spectrophotometer at the maximum wavelength
of QE (420 nm). Experiments were conducted in
triplicate. The TFC of each sample was calculated using
the standard QE curve (y = 0.0474x + 0.0076, R2 =
0.9985) and expressed as mg QE/g sample.
In vitro -amylase inhibitory activity. All samples
were prepared with various concentrations (i.e., 100–500
Makara J. Sci.

µg/mL for the combined extract and microcapsules and
10–50 µg/mL for acarbose). Then, 250 µL of the sample
solution was mixed with 250 µL of the α-amylase
enzyme solution (50 µg/mL) and incubated at 37 C for
30 min. Afterward, 250 µL of 1% starch solution (w/v)
was added and incubated at 25 C for 10 min.
Subsequently, the solution was mixed with 500 µL DNS
reagent and was incubated in boiling water for 5 min until
the solution turned brownish red. Finally, the solution
was cooled, and 5 mL of distilled water was added. The
absorbance of the mixed solution was measured at a
wavelength of 480 nm using a UV–Vis
spectrophotometer. Experiments were conducted in
triplicate. The calculation of the percent inhibition of the
α-amylase enzyme activity of the sample was conducted
using the following equation:
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝐸𝑛𝑧𝑦𝑚𝑒 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%)
=

𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
× 100%
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

The sample concentration and percent inhibition were
plotted on the x- and y-axes, respectively, in the linear
regression equation. The calculated results were
expressed as the IC50 (inhibitory concentration) value,
which is the capability of the inhibitor at a particular
concentration to inhibit 50% of α-amylase enzyme
activity.
Antioxidant activity assay using the DPPH method.
Samples with various concentrations (i.e., 10–50 µg/mL
for the R. tuberosa L. and C. caudatus K. extracts, 40–
120 µg/mL for the microcapsules, and 1–13 µg/mL for
ascorbic acid) were prepared. A 50 µg/mL DPPH
solution was added to each solution. The mixed solution
was incubated at room temperature for 30 min and kept
in the dark. Then, the absorbance was measured using a
UV–Vis spectrophotometer at 516 nm. Experiments were
conducted in triplicate. The percentage of antioxidant
activity was calculated using the following formula:
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝐸𝑛𝑧𝑦𝑚𝑒 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%)
=

𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
× 100%
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

The IC50 value was calculated using the linear regression
equation, with the sample concentration on the x-axis and
the percent antioxidant activity on the y-axis.
In vitro release study. In vitro release assay of the
microcapsule samples was conducted in two types of
medium, namely, simulated gastric fluid (HCl pH 1.2)
and simulated intestinal fluid (phosphate buffer pH 7.4).
The 2.5 mg microcapsule sample was immersed in 10 mL
of the medium at 37 C and stirred at a slow speed of 100
rpm. Then, 10 mL samples were taken at 30, 60, 90, and
June 2022  Vol. 26  No. 2
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120 min. Experiments were conducted in triplicate. The
concentration of the extract released from the
microcapsules was calculated as the TFC and expressed
as the percentage release using the following equation:

99

NH2 causes strong intramolecular repulsion, which will
reduce the bond strength between chitosan and Na-TPP
[32]. According to a previous study [33], at pH > 4, the
microcapsule matrix formed is weak because of the
deprotonation of NH2.

𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝐸𝑛𝑧𝑦𝑚𝑒 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%)
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
=
× 100%
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

FTIR, particle size distribution, and SEM analysis.
FTIR analysis of the dry samples in the form of KBr
pellets was conducted using a Fourier transform infrared
(FTIR) spectrophotometer at 4,000–400 cm−1. The
particle size distribution of the microcapsules was
determined using a PSA. The shape and morphology of
the microcapsules were observed using scanning electron
microscopy (SEM), with magnifications of ×7,000 to
×15,000.
Data analysis. The results were expressed as the mean ±
standard error of the mean. Statistical analysis was
performed using the Statistical Package for the Social
Sciences v.26 software, followed by one-way analysis of
variance and Tukey’s honestly significant difference, to
determine the significant difference. p < 0.05 was
considered a significant difference.

Results and Discussion
R. tuberosa L. and C. caudatus K. microcapsules were
produced using the spray drying method under the influences of pH, stirring time, and Na-TPP concentration.
The resulting data are shown in Figure 1. The optimum
microencapsulation conditions were achieved at pH 4,
0.15% Na-TPP concentration (b/v), and 60 min stirring
time, with 96.25% EE.
The microcapsules prepared at pH 4 exhibited the highest
EE. Chitosan is soluble in acidic pH with pKa below 6.3.
At pH 4, chitosan received more proton donors. Thus,
NH3+ ions increased because of the protonation of the
amine group (NH2) of chitosan. As a result, more ionic
bonds can be formed with the phosphate ion (P 3O105−) of
Na-TPP [31]. Therefore, the microcapsule matrix formed
is strong, and the number of encapsulated bioactive
compounds increases, thereby increasing the EE.
The results of this study are similar to those of previous
studies. At pH 4, a stoichiometric equilibrium of the
charge density of biopolymers with opposite signs is
achieved. Thus, in the design of microcapsules
containing chitosan, pH 4 is the most effective pH value
[28]. Meanwhile, at pH < 4, increasing protonation of
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In this study, the optimum microencapsulation conditions
were obtained at the Na-TPP concentration of 0.15%
(w/v). Figure 1B shows that the higher the Na-TPP
concentration used, the lower the EE of the
microcapsules. Meanwhile, the chitosan concentration
used in this study was 0.1% (w/v) under the same
conditions. The same results were obtained in previous
studies [34, 35], i.e., at a high Na-TPP concentration, the
number of P3O105− ions that would form ionic bonds with
NH3+ was not balanced. As a result, the microcapsule
matrix formed is weak. Therefore, the capability to
absorb R. tuberosa L. and C. caudatus K. extracts is
weak.
Stirring time is also a factor observed in this study. The
highest EE was obtained at a stirring time of 60 min.
Increasing the stirring time can reduce the size of the
resulting microcapsules. A high-intensity collision will
produce small particles, resulting in a large particle
surface area [30]. Therefore, the adsorbed extracts of R.
tuberosa L. and C. caudatus K. increased. However,
prolonged stirring can cause microcapsule aggregation.
This result is consistent with those of previous studies
[36–38].
For the first biological assay, the antidiabetic activity of
the samples was determined by an α-amylase inhibition
test. The samples used in this test were the combination
of R. tuberosa L. and C. caudatus K. extracts under the
optimum microencapsulation conditions and acarbose.
The results of the study are shown in Table 1.
The IC50 value of R. tuberosa L. and C. caudatus K.
extracts was 121.48 ± 0.88 µg/mL in terms of α-amylase
inhibitory activity, whereas that of microcapsules was
223.64 ± 0.81 µg/mL. The inhibitory activity of the
extract against α-amylase was higher than that of the
microcapsules because of the retention of some bioactive
compounds in the microcapsules. As a result, the
microcapsules did not release bioactive compounds
entirely. The primary purpose of microencapsulation is
not to increase biological activity but to maximize
protection against bioactive compounds [28]. Moreover,
with microencapsulation, the release of bioactive
compounds can be conducted in a controlled manner
[39]. Thus, the microcapsules of R. tuberosa L. and C.
caudatus K. acted as α-amylase inhibitors.

June 2022  Vol. 26  No. 2
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Figure 1. Encapsulation Efficiency of Ruellia tuberosa L. and Cosmos caudatus K. Microcapsules Prepared at Different (A) pH
values, (B) Na-TPP Concentrations (w/v (%)), and (C) Stirring Times

Table 1. IC50 Values of Ruellia tuberosa L. and Cosmos caudatus K. Extracts, Microcapsules, and Acarbose on the -amylase
Inhibition Assay

Samples
R. tuberosa L. and C. caudatus K. extracts
Microcapsules at pH 4, 0.15% (b/v) Na-TPP concentration, and 60 min stirring time
Acarbose

IC50 value (µg/mL)
121.48 ± 0.88
223.64 ± 0.81
19.58 ± 0.12

Table 2. Antioxidant Activity of R. tuberosa L. and C. caudatus K. Extracts, Microcapsules, and Ascorbic Acid

Samples
R. tuberosa L. and C. caudatus K. extracts
Microcapsules at pH 4, 0.15% (b/v) Na-TPP concentration, and 60 min stirring time
Ascorbic acid

IC50 value (µg/mL)
33.47 ± 0.03
104.05 ± 0.88
3.05 ± 0.05

Figure 2. Release Profile of the R. tuberosa L. and C. caudatus K. Microcapsules Prepared under the Optimum Conditions of
pH 4, 0.15% (b/v) Na-TPP Concentration, and 60 min Stirring Time at (A) pH 1.2 and (B) 7.4

Makara J. Sci.
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Figure 3. FTIR Spectra of (A) R. tuberosa L. and C. caudatus K. Extracts and (B) R. tuberosa L. and C. caudatus K.
Microcapsules Prepared under the Optimum Conditions of pH 4, 0.15% (b/v) Na-TPP Concentration, and 60 min
Stirring Time

Table 3. Assignment of FTIR Spectra

Peak
Number

Assignment for R. tuberosa L. and
C. caudatus K. extracts [53–56]

Assignment for R. tuberosa L and
C. caudatus K. microcapsules [28, 53–56]

1

3,400.09 cm−1 for O–H alcohol

3,395.81 cm−1 for alcohol

2

2,928.01 cm−1 for C–H methylene

2,925.16 cm−1 for C–H methylene

3

1,617.32 cm−1 for C=C aromatic and C=O ketone

1,570.26 cm−1 for C=C aromatic

5

1,386.28 cm−1 for C–H alkene

1,411.95 cm−1 for C=C aromatic

6

1,076.79 cm−1 for C–O–C aryl alkyl ether

1,213.71 cm−1 for P=O
1,155.23 cm−1 for C–N

Figure 4. SEM Images of (A) R. tuberosa L. and C. caudatus K. Extracts and (B) R. tuberosa L. and C. caudatus K.
Microcapsules Prepared under the Optimum Conditions of pH 4, 0.15% (b/v) Na-TPP Concentration, and 60 Min
Stirring Time. The Magnification was ×7,000
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Figure 5. Particle Size Distribution of R. tuberosa L. and C. caudatus K. Microcapsules Prepared under the Optimum Conditions of pH 4, 0.15% (b/v) Na-TPP Concentration, and 60 Min Stirring Time

Acarbose, as a reference, had an IC50 value of 19.58 ±
0.12 µg/mL. The smallest IC50 value indicates the highest
α-amylase inhibitory activity. Compared with extracts
and microcapsules, acarbose exhibited the best inhibitory
activity against α-amylase. These results are consistent
with those of previous studies because acarbose is a competitive inhibitor for α-amylase [40]. Furthermore, although the R. tuberosa L. and C. caudatus K. extracts contain several bioactive compounds [3, 10], not all of these
compounds have inhibitory activity against α-amylase
[28]. Flavonoid compounds are bioactive compounds
that can act as α-amylase inhibitors. Flavonoids bind to
α-amylase covalently and alter their activity because of
their capability to form quinones or lactones that react
with the nucleophilic group of the enzyme [41].
For the second biological assay, a test was conducted to
confirm the antioxidant activity of the samples. The antioxidant activity test results are shown in Table 2. The
samples used were the combination of R. tuberosa L and
C. caudatus K. extracts under the optimum microencapsulation conditions and ascorbic acid as a positive reference.
The antioxidant activity test was conducted using the
DPPH reagent. The DPPH radical is an organic compound containing unstable nitrogen and produces a dark
purple solution color [42]. Antioxidants, such as ascorbic
acid, act as reducing agents to stabilize these free radicals. As a result, a colorless solution is obtained [43, 44].
As previously reported, antioxidant activity is also required to treat diseases associated with free radical
Makara J. Sci.

involvement, such as diabetes [45]. Based on the IC50
data shown in Table 3, the antioxidant activity of microcapsules (104.05 ± 0.88 µg/mL) was lower than those of
extracts (33.47 ± 0.03 µg/mL) and ascorbic acid (3.05 ±
0.05 µg/mL). Nevertheless, the R. tuberosa L. and C.
caudatus K. microcapsules are categorized as active antioxidants (100 < IC50 value < 150 µg/mL). Moreover,
the R. tuberosa L. and C. caudatus K. extracts are classified as very active antioxidants (IC50 < 50 mg/mL) but
are less active than ascorbic acid [42].
The in vitro release study is a crucial parameter used to
test the capability of microcapsules for drug administration in the systemic circulation [46]. In the determination
of oral drug candidates, the test for the release of bioactive compounds from the microcapsule matrix was conducted at pH 1.2 (artificial gastric fluids) and pH 7.4 (artificial intestinal fluids). In this study, the release of extracts was triggered by pH stimulation. In general, under
acidic pH conditions in gastric fluids, microcapsule formulations can maintain the release of the bioactive compounds for 15 min to 2 h. Furthermore, the active ingredients are released when they reach the intestines under
alkaline pH conditions. The release of bioactive compounds in the intestinal organs lasts for 2 h until they penetrate the bloodstream [47, 48]. Therefore, the release test
was conducted in acid and alkaline media for 2 h.
The release profile study at pH 1.2 (Figure 2) showed that
the percentage release of the R. tuberosa L. and C. caudatus K. extracts was 4.99% in the first 30 min and increased to 5.99% at 120 min. At pH 1.2, the NH 2 group
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is protonated into NH3+; thus, chitosan becomes positively charged. Under acidic pH conditions, H+ ions interact with cations on the surface of chitosan. As a result,
the chitosan–Na-TPP cleavage process was limited,
which slowed the release of the extract [49]. By contrast,
the percentage release of extract by microcapsules at pH
7.4 was 30.60% in 30 min and reached 58.96% in 120
min. More extracts were released under alkaline pH conditions because of the deprotonation of NH 3+ ions from
chitosan into a non-ionized state, resulting in the breakdown of the bond between chitosan and Na-TPP matrix
[49, 50].
Microcapsules protect and control the release of extracts
when they reach the systemic circulation [20, 51]. Microcapsules are administered through absorption in the gastrointestinal tract (Sabra & Billa, 2020). Chitosan–NaTPP-based microcapsules are expected to be more stable
in acidic pH conditions in gastric fluids than in alkaline
pH conditions. Moreover, the amount of extracts released
from the coating matrix is expected to be higher at alkaline pH conditions in intestinal fluids so that a larger
amount of extracts can be absorbed into the bloodstream
and the required therapeutic effect can be achieved [46,
49]. Although the results of this study are consistent with
those of previous studies [46, 49], the percentage of R.
tuberosa L. and C. caudatus K. extracts released at pH
7.4 was only 58.98%. Under alkaline pH conditions, the
retention of the extract in the microcapsules was caused
by the electrostatic repulsion of the ionized group of chitosan [52]. Therefore, the microcapsules could not release all of the extracts at 120 min.
The FTIR spectra enable the identification of functional
groups in the R. tuberosa L. and C. caudatus K. microcapsules. Figure 3 shows the FTIR spectra. Meanwhile,
Table 3 lists the assignments of the absorption functional
groups.
The spectral analysis showed that the R. tuberosa L. and
C. caudatus K. extracts exhibited stretching vibration of
the O–H group at 3,400.09 cm−1. Then, absorption at
2,928.01 cm−1 indicated the C–H stretching vibration of
the methylene group. The C=C stretching aromatic and
C=O stretching ketone vibrations were detected at
1,617.32 cm−1. Furthermore, absorption peaks detected at
1,386.28 and 1,076.79 cm−1 were interpreted as C–H
stretching vibrations of alkenes and C–O–C stretching vibrations of aryl alkyl ethers, respectively [53–56]. According to previous studies [28, 30, 57], stretching vibrations at approximately 1,386.28 and 1,076.79 cm −1 indicated the typical absorption of the R. tuberosa L extract.
Meanwhile, the wavenumber at approximately 1,617.32
cm−1 indicated the specific absorption of the C. caudatus
K. extract.
By contrast, the microcapsule FTIR spectra indicated a
shift in the stretching vibrational spectra of the O–H
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alcohol, C–H methylene, and C=C aromatic groups.
Moreover, the occurrence of new absorption indicated
the presence of P=O functional group vibrations from
Na-TPP (1,213.71 cm−1) and C–N stretching vibrations
from chitosan (1,155.23 cm−1) [28]. The occurrence of
these two types of absorption refers to the polymer and
cross-linker used to manufacture the microcapsules.
Characterization was then conducted to determine the
surface morphology and size of the obtained microcapsules. Figure 4A and 4B shows the differences in SEM
results between extracts and microcapsules. The microcapsules were spherical and nearly uniform in size and
had rough surfaces. In this study, the morphology of the
obtained microcapsules was similar to that in a previous
study [28]. Microcapsule analysis using a PSA aims to
determine the particle size distribution. The mean diameter of the microcapsules was 132.08 µm, as shown in
Figure 5. The particle size distribution was determined to
be polymodal. The polymodal distribution is particularly
prevalent for granular particles [58]. Nevertheless, the
microcapsules obtained in this study did not meet the requirements for the particle size produced from the spray
drying process (10–100 μm) [59]. The inlet temperature
of 105 ℃ used in spray drying was high. At high temperatures, water vapor is difficult to diffuse through the particle surface because of the formation of a crust layer on
the droplet surface. As a result, the microcapsule particle
size is large [60].

Conclusion
In this study, microencapsulation of the R. tuberosa L.
and C. caudatus K. extracts was successfully conducted.
The investigated parameters include pH variation, NaTPP concentration, and stirring time. The microcapsules
were produced using the spray drying technique under
the optimum microencapsulation conditions of pH 4,
0.15% (w/v) Na-TPP concentration, and 60 min stirring
time. The microcapsules have inhibitory activity against
α-amylase with an IC50 value of 223.64 ± 0.81 µg/mL.
Furthermore, the microcapsules have antioxidant activity
with an IC50 value of 104.05 ± 0.88 µg/mL. The in vitro
release test showed that the R. tuberosa L. and C. caudatus K. extracts were more easily released at pH 7.4 than
at pH 1.2. FTIR analysis showed the cross-linking between chitosan and Na-TPP. SEM analysis showed that
the microcapsules were spherical and nearly uniform in
size and had rough surfaces. Meanwhile, particle size
analysis showed that the microcapsules had a particle diameter of 132.08 µm.
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